作者
Pawel Kermer, Christoph C Eschenfelder, Hans-Christoph Diener, Martin Grond, Yasser Abdalla, Alexej Abraham, Katharina Althaus, Gebhard Becks, Jörg Berrouschot, Jörg Berthel, Felix J Bode, Lothar Burghaus, Hakan Cangür, Michael Daffertshofer, Sebastian Edelbusch, Jürgen Eggers, Rüdiger Gerlach, Klaus Gröschel, Florian Große-Dresselhaus, Albrecht Günther, Claus G Haase, Carl-Albrecht Haensch, Andreas Harloff, Joseph G Heckmann, Valentin Held, Maren Hieber, Andreas Kauert, Rolf Kern, Thomas Kerz, Martin Köhrmann, Peter Kraft, Peter Kühnlein, Jan Latta, Elke Leinisch, Arne Lenz, Christoph Leithner, Tobias Neumann-Haefelin, Mathias Mäurer, Wolfgang Müllges, Christian H Nolte, Mark Obermann, Someieh Partowi, Peer Patzschke, Sven Poli, Ulrich Pulkowski, Jan Purrucker, Torsten Rehfeldt, Peter A Ringleb, Joachim Röther, Raluca Rossi, Hazem El-Sabassy, Oliver Sauer, Gabriele Schackert, Niklas Schäfer, Peter D Schellinger, Andreas Schneider, Ramona Schuppner, Stefan Schwab, Olav Schwarte, Rüdiger J Seitz, Sebastian Senger, Yogesh P Shah, Eckhart Sindern, Paul Sparenberg, Thorsten Steiner, Kristina Szabo, Christian Urbanek, Bettina von Sarnowksi, Karin Weissenborn, Peter Wienecke, Karsten Witt, Robert Wruck, Silke Wunderlich
发表日期
2020/8
期刊
International Journal of Stroke
卷号
15
期号
6
页码范围
609-618
出版商
SAGE Publications
简介
Background
Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth.
Aims
To provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of acute ischemic stroke or intracranial hemorrhage.
Methods
Retrospective data collected from German neurological/neurosurgical departments administering idarucizumab following product launch from January 2016 to August 2018 were used.
Results
One-hundred and twenty stroke patients received idarucizumab in 61 stroke centers. Eighty patients treated with …
学术搜索中的文章
P Kermer, CC Eschenfelder, HC Diener, M Grond… - International Journal of Stroke, 2020